TABLE 2.
Pooled Colectomy-Free Survival (Random-Effects Model), Expressed as N% (95% CI)
| Month 1 | Month 3 | Month 12 | |
|---|---|---|---|
| Overall colectomy free-survival | 85.7% (82.0%–89.0%; I2 = 70.6%; 36 studies, 1550/1860 cases) |
79.7% (75.48%–83.6%; I2 = 77%; 36 studies, 1659/2129 cases) |
69.8% (65.7%–73.7%; I2 = 67%; 33 studies, 1357/1943 cases) |
| 5-mg/kg single dose | 78.8% (68.4%–88.0%; I2 = 40.2%; 9 studies, 127/168 cases) |
67.3% (57.1%–76.8%; I2 = 55.1%; 10 studies, 200/307 cases) |
57.0% (40.7%–72.7%; I2 = 60.2; 6 studies, 75/127 cases) |
| 5-mg/kg multiple dose | 90.0% (86.1%–93.3%; I2 = 67.7%; 25 studies, 1027/1189 cases) |
85.1% (80.9%–89.0%; I2 = 71.7%; 28 studies, 1125/1379 cases) |
72.8% (68.2%–77.2%; I2 = 60.2%; 25 studies, 881/1231 cases |
| 5-mg/kg standard 026 induction | 89.4% (83.9%–93.9%; I2 = 81.5%; 24 studies, 882/1038 cases) |
84.0% (78.3%–89.1%; I2 = 80.5%; 25 studies, 923/1152 cases) |
73.8% (67.9%–79.4%; I2 = 74.6%; 24 studies, 772/1080 cases) |
| 5-mg/kg accelerated induction | 86.3% (78.5%–92.8%; I2 = 21.7%; 6 studies, 125/145 cases) |
79.7% (72.3%–86.2%; I2 = 0%; 6 studies, 115/145 cases) |
71.2% (63.1%–78.6%; I2 = 0%; 5 studies, 103/145 cases) |
| Dose-intensified induction | 84.8% (78.0%–90.6%; I2 = 46.1%; 11 studies, 274/325 cases) |
78.5% (70.8%–85.4%; I2 = 49.2%; 11 studies, 254/325 cases) |
70.1% (60.2%–79.2%; I2 = 65.9%; 10 studies, 231/321 cases) |
| 10-mg/kg multiple-dose induction | 81.0% (65.4%–93.2%; I2 = 39.9%; 4 studies, 59/75 cases) |
76.7% (59.1%–91.1%; I2 = 48.3%; 4 studies, 56/75 cases) |
69.6% (54.0%–83.3%; I2 = 37.3%; 3 studies, 50/71 cases) |
| 10-mg/kg standard schedule | 84.9% (71.6%–95.0%; I2 = 0%; 2 studies, 36/43 cases) |
79.4% (53.9%–97.1%; I2 = 50.1%; 2 studies, 35/43 cases) |
71.5% (36.4%–96.9%; I2 = 69.7%; 2 studies, 33/43 cases) |
| 10-mg/kg accelerated schedule | 92.7% (60.3%–100%; I2 = 43.7%; 3 studies, 13/15 cases) |
88.3% (63.5%–100%; I2 = 68.9%; 3 studies, 12/15 cases) |
78.8% (8.3%–100%; I2 = 81.7%; 2 studies, 8/11 cases) |